問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (非在職)

Division of Obstetrics & Gynecology

更新時間：2023-09-19

林政道Lin, Cheng-Tao
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 10 個月

  • 51424@cgmh.org.tw

Recruiting Trial

22Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林政道

List

34Cases

2021-05-21 - 2024-06-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2022-02-12 - 2025-09-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Terminated5Sites

2004-09-01 - 2005-04-30

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2025-07-01 - 2029-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2010-11-01 - 2016-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2008-06-01 - 2010-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2019-06-10 - 2024-04-24

Phase III

A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer (CALLA)

  • Condition/Disease

    Locally Advanced Cervical Cancer

  • Test Drug

    Durvalumab

Participate Sites
6Sites

Terminated6Sites

2014-10-01 - 2021-04-20

Phase III

Randomized, Double blind, Placebo-controlled Trial of Z-100 plus Radiation Therapy in Patients with Locally Advanced Cervical Cancer — A Phase III trial

  • Condition/Disease

    FIGO stage IIIB cervical cancer

  • Test Drug

    Z-100

Participate Sites
17Sites

Terminated17Sites

2018-10-01 - 2021-11-30

Phase II

A Randomized Double-Blind, Placebo-controlled Phase II Trial With Safety Run-In of Intramuscular pNGVL4a-Sig/E7(Detox)/HSP70 and TA-CIN for the Treatment of Patients With HPV16+ Atypical Squamous Cells of Undetermined Significance (ASC-US) or Cannot Exclude High Grade SIL (ASC-H) Cytology or Low-grade Squamous Intraepithelial Lesion (LSIL)

  • Condition/Disease

    AS-CUS/ASC-H Atypical Squamous Cells, Cannot Rule Out High-Grade Squamous Intra-Epithelial Lesion/LSIL

  • Test Drug

    pNGVL4a-Sig/E7(detox)/HSP70；TA-CIN

Participate Sites
1Sites

Recruiting1Sites

2011-04-01 - 2018-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB